Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Has Consensus Target Price of $642.33

Thermo Fisher Scientific Inc. (NYSE:TMO) has been given an average rating of “Moderate Buy” by the twenty-six research firms that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, nineteen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $654.05.

A number of brokerages have issued reports on TMO. Scotiabank assumed coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an “outperform” rating on the stock. Morgan Stanley increased their price target on Thermo Fisher Scientific from $650.00 to $730.00 and gave the stock an “overweight” rating in a research report on Monday. UBS Group raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $540.00 to $730.00 in a report on Tuesday, September 8th. Jefferies Financial Group reissued a “buy” rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Finally, Stifel Nicolaus set a $650.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, August 5th.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 275 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $77,707,171.25. The trade was a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. This represents a 54.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 73,768 shares of company stock worth $44,122,820. Insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TMO. James T. Borello RIA acquired a new stake in shares of Thermo Fisher Scientific during the third quarter valued at about $57,000. V Square Quantitative Management LLC grew its holdings in shares of Thermo Fisher Scientific by 2.2% during the third quarter. V Square Quantitative Management LLC now owns 2,451 shares of the medical research company’s stock worth $1,655,000 after purchasing an additional 53 shares during the last quarter. YANKCOM Partnership increased its stake in shares of Thermo Fisher Scientific by 4.7% in the third quarter. YANKCOM Partnership now owns 1,405 shares of the medical research company’s stock valued at $948,000 after buying an additional 63 shares during the period. Fortitude Advisory Group L.L.C. raised its holdings in Thermo Fisher Scientific by 5.7% in the 3rd quarter. Fortitude Advisory Group L.L.C. now owns 1,091 shares of the medical research company’s stock valued at $736,000 after buying an additional 59 shares during the last quarter. Finally, Community Financial Services Group LLC grew its position in shares of Thermo Fisher Scientific by 13.9% in the 3rd quarter. Community Financial Services Group LLC now owns 927 shares of the medical research company’s stock valued at $605,000 after buying an additional 113 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $690.22 on Wednesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The firm has a market cap of $255.21 billion, a price-to-earnings ratio of 29.23, a P/E/G ratio of 2.91 and a beta of 0.87. The stock’s fifty day moving average price is $637.32 and its two-hundred day moving average price is $548.10. Thermo Fisher Scientific has a one year low of $435.27 and a one year high of $704.00.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter in the previous year, the business posted $4.28 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts forecast that Thermo Fisher Scientific will post 25.13 EPS for the current year.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Analysts expect third-quarter adjusted earnings of approximately $6.40 per share, with results likely to show whether Thermo Fisher’s growth is continuing into the second half of 2026. Thermo Fisher Scientific Q3 2026 Preview
• Positive Sentiment: Recent investor commentary cites strong operating results and a recovery in Thermo Fisher’s Life Sciences Solutions business, while academic and government research spending remain important sources of demand. Thermo Fisher Scientific Outperforms on Strong Results and Life Sciences Recovery Academic and Government Spending Powers Thermo Fisher
• Positive Sentiment: Thermo Fisher is positioned to benefit from growth in immuno-oncology diagnostics, a market forecast to reach $11.1 billion by 2030, although the opportunity is shared with competitors including Roche, Illumina and Agilent. Immuno-Oncology Diagnostics Market Forecast
• Neutral Sentiment: Analysts are also examining key metrics such as segment performance and margins for the September quarter; those details could determine whether the expected earnings growth is high quality. Analyst Projections for Thermo Fisher Key Metrics
• Negative Sentiment: Valuation concerns may be weighing on the shares. Thermo Fisher trades at a premium earnings multiple after a substantial advance and has reached a new 52-week high, prompting some analysts to maintain a cautious or “hold” view despite strong growth prospects. Thermo Fisher Strong Growth, Even Higher Stock Price

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.